A Phase 1 interventional study of SAR153191-P3 drug product and SAR153191-P2 drug product in Rheumatoid Arthritis, sponsored by Sanofi. Completed. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.
Sponsored by Sanofi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 14th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 1, and was the 21st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 29th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2010, is one of 9 in phase 1, and was the 33rd registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
To determine the tolerability of different SAR153191 drug products that differ with respect to manufacturing processes and formulation, at different concentrations and doses, after administration of single subcutaneous doses to healthy male subjects.
Secondary objectives:
To determine the pharmacokinetic profile of the different SAR153191 drug products administered subcutaneously.
To assess the safety of the different SAR153191 drug products administered subcutaneously.
Up to 35 Days
Inclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SAR153191 - P3 drug product concentration 1 dose 1
Drug: SAR153191-P3 drug product
SAR153191 - P2 drug product concentration 2 dose 2
Drug: SAR153191-P2 drug product
SAR153191 - P3 drug product concentration 2 dose 2
Drug: SAR153191-P3 drug product
SAR153191 - P3 drug product concentration 3 dose 3
Drug: SAR153191-P3 drug product
SAR153191 - P2 drug product concentration 2 dose 3
Drug: SAR153191-P2 drug product
SAR153191 - P3 drug product concentration 2 dose 3
Drug: SAR153191-P3 drug product
SAR153191 - CIF3 drug product concentration 2 dose 3
Drug: SAR153191-C1F3 drug product
Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Also known as: SAR153191
Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Also known as: SAR153191
Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Also known as: SAR153191
Number of participants reporting injection site reactions
Injection site reactions include pain, erythema an edema.
Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21, and 35 following SAR153191 administration
Pharmacokinetics: Cmax
Maximum plasma concentration observed
Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration
Pharmacokinetics: tmax
First time to reach Cmax
Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration
Pharmacokinetics: AUClast
Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time
Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration
Pharmacokinetics: AUC
Area under the plasma concentration versus time curve extrapolated to infinity
Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration
Pharmacokinetics: t1/2z
Terminal half-life associated with the terminal slope (λz)
Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration
Safety: Number of participants who experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)
Time frame: Up to 35 Days
Incidence of anti-SAR153191 antibodies
Time frame: At Day 1 predose and on Days 7, 21, and 35 (plus follow-up if positive)
No study locations are listed for this record.
Ran from Jul 2010 to primary completion in Dec 2010, 5 months.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 5 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab